mTORC1- and mTORC2-activating mutations in MTOR and RHEB

Slides:



Advertisements
Similar presentations
Fig. S1 1 Oxygen consumption rate (pmol/sec/10⁶cells) shLKB1#1 control * untreated 25 μM erlotinib H358 Vector LKB1 Oxygen consumption rate (pmol/sec/10⁶cells)
Advertisements

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.
Nephrin mutants enhance ATF6‐luciferase reporter activity
Volume 13, Issue 2, Pages (February 2011)
Suppression of ENTPD5 in human NSCLC cells results in decreased AKT activity and decreased proliferation under low-serum conditions. Suppression of ENTPD5.
Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia by Hironori.
Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.
PGAM5 dephosphorylates ASK1.
Requirement of Gαi1/3–Gab1 Signaling Complex for Keratinocyte Growth Factor– Induced PI3K–AKT–mTORC1 Activation  Yi-ming Zhang, Zhi-qing Zhang, Yuan-yuan.
Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.
DEAR1 binds to SMAD3 and induces SMAD3 ubiquitination.
Knock-down of endogenous PINK1 abrogates Parkin Ser65 phosphorylation.
Teruaki Fujishita, Masahiro Aoki, Makoto M. Taketo  Gastroenterology 
Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function by Alfonso Catalano, Paola Caprari, Simona Moretti, Monica.
Volume 13, Issue 2, Pages (February 2011)
Volume 137, Issue 5, Pages (May 2009)
Figure 3 Complete loss of neurofilament light (NEFL) protein in cultured patient neurons Complete loss of neurofilament light (NEFL) protein in cultured.
NF1 downregulation activates MAPK pathway signaling.
Volume 21, Issue 4, Pages (February 2006)
The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.
Differential regulation of mTORC1 by leucine and glutamine
Elucidating the effects of disease-causing mutations on STAT3 function in autosomal- dominant hyper-IgE syndrome  Simon J. Pelham, MSc, Helen C. Lenthall,
PRAS40 Is an Insulin-Regulated Inhibitor of the mTORC1 Protein Kinase
Volume 92, Issue 3, Pages (September 2017)
Keratinocyte growth factor promotes goblet cell differentiation through regulation of goblet cell silencer inhibitor  Dai Iwakiri, Daniel K. Podolsky 
KIF1Bβ promotes DHX9 nuclear localization.
Serine Phosphorylation by mTORC1 Promotes IRS-1 Degradation through SCFβ-TRCP E3 Ubiquitin Ligase  Yosuke Yoneyama, Tomomi Inamitsu, Kazuhiro Chida, Shun-Ichiro.
PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD, leading to mTORC2 activation. PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD,
Volume 10, Issue 1, Pages (July 2002)
The Actin-Bundling Protein Palladin Is an Akt1-Specific Substrate that Regulates Breast Cancer Cell Migration  Y. Rebecca Chin, Alex Toker  Molecular.
Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.
Ken Inoki, Tianqing Zhu, Kun-Liang Guan  Cell 
Glutaminolysis Activates Rag-mTORC1 Signaling
The selective PI3K inhibitor A66 suppresses PIP3 accumulation, AKT phosphorylation at Thr308, and YAP/TAZ–regulated gene expression in PDAC cells. The.
Role of HER2 in mediating acquired resistance to EGFR inhibition.
Rsk1 mediates a MEK–MAP kinase cell survival signal
Figure 2 The K19del mutation affects the expression and solubility of CHP1 The K19del mutation affects the expression and solubility of CHP1 (A) Western.
The role of SRC-C3G-RAP1 signaling in transformation induced by CRKL
Hua Gao, Yue Sun, Yalan Wu, Bing Luan, Yaya Wang, Bin Qu, Gang Pei 
USP2a overexpression modifies the microRNA expression profile of prostate cells. USP2a overexpression modifies the microRNA expression profile of prostate.
TRAF4 is required for EGFR activation in response to EGF stimulation.
AMPK-mediated mTORC2 signaling does not require mTOR Ser1261phosphorylation. AMPK-mediated mTORC2 signaling does not require mTOR Ser1261phosphorylation.
Figure 4 DNM1 mutations affect protein levels and self-dimerization (A) HeLa cells were transfected with green fluorescent protein (GFP)-tagged mutant.
P38 activation mediates chronic insulin-induced IRS1 and IRS2 degradation and is involved in myocardial insulin resistance in vitro. p38 activation mediates.
Mechanism of Akt1 in promoting reprogramming.
JAK3A572V mutation causes constitutive JAK3 activity and IL-2–independent proliferation of NKTCL cells. JAK3A572V mutation causes constitutive JAK3 activity.
Mutant MFN2 proteins have normal half-lives and are properly localized to mitochondria. Mutant MFN2 proteins have normal half-lives and are properly localized.
PKM2 is tyrosine phosphorylated and inhibited by FGFR1 in cancer cells with oncogenic or overexpressed FGFR1. PKM2 is tyrosine phosphorylated and inhibited.
A, scheme of the APC cDNA and the mutant APC cDNAs which were used for reporter gene assays. A, scheme of the APC cDNA and the mutant APC cDNAs which were.
Phosphorylation and Functional Inactivation of TSC2 by Erk
CCG regulates cellular localization and blocks target gene expression of MRTF. A, SK-Mel-147 cells were cotransfected with RhoC and the SRE.L reporter.
Fig. 3 Active p38γ dissociates PSD-95/tau/Fyn/NR complexes.
Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.
Effect of mutations of the SRE and RCE on the Akt activation of the Fra-1 promoter. Effect of mutations of the SRE and RCE on the Akt activation of the.
Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.
Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.
MDA-468TR-PTEN (with and without 100 ng/ml doxycycline) and MDA-468TR-vector (with dox) were serum starved overnight and the following day treated for.
Gain-of-function conferred by RNF31 SNPs
Fig. 2 Viperin promotes methionine oxidation of KSHV helicase.
Pirh2 represses p73-dependent transactivation.
Knockdown of ERBB3, NRG1, or ERBB2 in H358-TwistER cells reduces basal PI3K–AKT signaling and ablates serum-independent proliferation before EMT. A and.
AKT activation in HCC2429 is SRC- but not Notch-dependent.
Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.
MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.
Investigation of reactivity of D14 HLA-A
Volume 58, Issue 3, Pages (May 2015)
A, indicated model systems were cultured in media containing complete serum, harvested, and lysed; total protein was separated by SDS-PAGE, transferred.
BRCA1 sequence variants classified as pathogenic do not restore HR
CREB1 binds at the proximal region of the TGFB2 promoter and induces its transcriptional activation. CREB1 binds at the proximal region of the TGFB2 promoter.
TCTP enhances the protein stability of Pim-3 by blocking the ubiquitin–proteasome degradation of Pim-3. TCTP enhances the protein stability of Pim-3 by.
Presentation transcript:

mTORC1- and mTORC2-activating mutations in MTOR and RHEB mTORC1- and mTORC2-activating mutations in MTOR and RHEB. A, several distinct mTOR mutants induce S6K1 phosphorylation. mTORC1- and mTORC2-activating mutations in MTOR and RHEB. A, several distinct mTOR mutants induce S6K1 phosphorylation. HEK-293T cells were cotransfected with HA-GST-S6K1 and mTOR WT or mutant cDNAs in expression vectors followed by whole-cell lysis 48 hours after transfection. The lysates were then immunoblotted for the indicated proteins and the phosphorylation state of S6K1. Densitometry of phosphorylated (P) S6K1 versus HA-GST-S6K1 from three separate experiments is shown on the right; the error bars represent SEM. B, several distinct mTOR mutants induce 4EBP1 phosphorylation. HEK-293T cells were cotransfected with HA-GST-4EBP1 and WT or mutant MTOR cDNAs in expression vectors followed by whole-cell lysis 48 hours after transfection. The lysates were then immunoblotted for the indicated proteins and the phosphorylation state of 4EBP1. Densitometry of p4EBP1 versus HA-GST-4EBP1 from three separate experiments is shown on the right; the error bars represent SEM. C, several mTOR mutants induce AKT1 phosphorylation. HEK-293E cells were cotransfected with HA-GST-AKT1 and mTOR WT or mutant cDNAs in expression vectors followed by whole-cell lysis 48 hours after transfection and an overnight 0.5% serum starvation. The lysates were then immunoblotted for the indicated proteins and the phosphorylation state of AKT1. Densitometry of pAKT1 versus HA-GST-AKT1 from three separate experiments is shown on the right; the error bars represent SEM. D, the C1483 cluster harbors nonrecurrent mTORC1-activating mutations from patients with kidney cancer. HEK-293T cells were cotransfected with HA-GST-S6K1 and mTOR WT or mutant cDNAs in expression vectors followed by whole-cell lysis 48 hours after transfection. The lysates were then immunoblotted as above. Densitometry of pS6K1 versus HA-GST-S6K1 from three separate experiments is shown on the right; the error bars represent SEM. E, RHEB1 mutants induce S6K1 phosphorylation. HEK-293T cells were transfected with WT or mutant RHEB1 cDNAs in expression vectors followed by whole-cell lysis 48 hours after transfection. The lysates were then immunoblotted as above. Densitometry of pS6K1 versus total S6K1 from three separate experiments is shown on the right; the error bars represent SEM. In all cases, *, P < 0.1 and **, P < 0.01. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; s.e., short exposures; l.e., long exposures. Brian C. Grabiner et al. Cancer Discovery 2014;4:554-563 ©2014 by American Association for Cancer Research